

Company name: **Neurolief**

Website: <https://neurolief.com/>

Name: **Amit Dar (Founder & CTO)**

email: **amit.dar@neurolief.com**

CATEGORY: **Medical Devices**

Select up to two SESSIONS per abstract from the list below *
(Delete sessions you are not selecting)

- **Rewiring the Brain; Breakthroughs in Neurotech and Neuromodulation**

Transforming Depression Treatment with a Novel At-Home Brain Neuromodulation Technology

Executive Summary

Neurolief is a neurotechnology company developing a physician-prescribed, home-based therapy for Major Depressive Disorder (MDD). Its novel neuromodulation technology addresses a critical unmet need in patients who do not respond to pharmacological treatments. Current neuromodulation options such as transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT) are restricted to in-clinic settings and require frequent visits to specialized facilities, limiting accessibility for most patients. Neurolief's solution delivers an effective brain stimulation therapy for treatment-resistant depression at home, under remote physician supervision. The company recently completed a pivotal clinical study - the first-ever randomized controlled trial to demonstrate success in a non-pharmacological home therapy for treatment-resistant depression. This achievement signals a paradigm shift in how a novel neuromodulation technology can become accessible for the millions in need.

Core Technology

Neurolief's proprietary technology is based on a multi-channel neuromodulation system that precisely stimulates multiple cranial nerve pathways simultaneously, targeting neural circuits involved in mood regulation. The therapy is delivered through a head-worn device that applies adaptive electrical pulses via three independent channels. The system integrates with a digital platform that collects and analyzes real-time treatment data, enabling physicians to monitor patient progress remotely, adjust protocols as needed, and improve adherence. This physician-controlled, data-driven approach ensures personalized care with the convenience of at-home treatment.

Product Profile

Proliv™Rx is Neurolief's lead product. Following successful completion of a pivotal randomized controlled trial, Proliv™Rx is positioned as the first validated home-based neuromodulation therapy for treatment-resistant depression. The market potential is substantial. Millions of patients worldwide are unresponsive to medication and face barriers

accessing in-clinic therapies. Proliv™Rx offers a scalable, highly effective alternative with potential for widespread impact in mental health care. Neurolief is currently preparing for commercial launch, with regulatory pathways and go to market infrastructure advancing.

Business Strategy

Neurolief aims to deploy Proliv™Rx through specialist prescribers and major healthcare networks. Short-term revenue will be driven by early partnerships and payer engagement. Long-term growth will stem from international expansion, broader clinical adoption, and national reimbursement programs.

What's Next

While awaiting FDA approval in the coming months, Neurolief is finalizing its commercial launch plans and expanding operational infrastructure. Key priorities include generating real-world evidence, optimizing product performance, and executing strategic investments to support sustainable scalability and successful global market entry.